News

Migraine remains one of the most common and disabling neurological disorders worldwide. Despite the introduction of new pharmacologic treatments—including CGRP monoclonal antibodies and gepants—a substantial proportion of patients continue to experience inadequate symptom control, intolerance to medications, and desire non-pharmacologic treatment options. Neuromodulation for the treatment of headac…

Neurotech Reports, the publisher of the Neurotech Business Report and BioElectRx Business Report newsletters, announced that the 2026 Bioelectronic Medicine Forum will take place on April 14, 2026. The one-day event will be held at the New York Academy of Medicine in Manhattan. Several new speakers and presenters have been added to the agenda at the Ninth Annual event. The new speakers include Guan…

The 2026 LSI USA conference, held in Dana Point, CA earlier this month, offered a dynamic platform for neurotech firms to demonstrate their latest advances and share insights with industry leaders, investors, and healthcare professionals. This year’s event underscored the rapid evolution of neurotechnology and its growing impact within the broader life sciences sector. A session devoted to SetPoint…

By now, many of our readers will have heard the news that Neurotech Reports has been acquired . We want to let you all know what that means for readers of this publication and attendees at our conferences. And the bottom line is that our being part of a larger organization with experience and expertise in healthcare industry publications and conferences can only benefit our readers, attendees, sponsors, and staff.

Competition in the market for tibial nerve stimulation systems to treat overactive bladder continues to intensify in the months following Boston Scientific’s, announcement to acquire Valencia Technologies [BBR Jan26 p6]. Earlier this month, Medtronic, which already competes with Boston Scientific in the implanted sacral nerve stimulation market, published positive results for its Altaviva TNS system in The Journal of Urology.

The market for stroke rehabilitation continues to advance as existing players and new entrants offer novel therapeutic approaches and pursue commercial development. There appears to be room in this space for vendors of both implanted and noninvasive neurotech therapies. Earlier this month, CorTec GmbH, a European manufacturer of active implantable medical technologies, announced the successful seco…

The road to developing a viable visual neuroprosthetic system to restore sight has been long and difficult. But several vendors remain in the game and much of the activity involves cortical stimulation approaches. At last month’s NANS annual meeting, Nader Pouratian, professor and chair, department of neurological surgery at UT Southwestern Medical Center, presented long-term results from the Orion…

At the 2026 meeting of the North American Neuromodulation Society in Las Vegas, Neurotech Reports editors, in conjunction with Nandan Lad from Duke University, produced a pre-conference workshop devoted to neurotech commercialization. The i3 program, which stands for invention, investment, and invigoration, is an opportunity for the neuromodulation community to explore business topics that aren’t generally covered in the meeting’s scientific sessions..

The ethical issues surrounding the use of animals in clinical trials and scientific experiments has been a source of controversy since the early days of medical research. For the neurotechnology industry, animal research—and primate research in particular—has been at the forefront of public awareness. The treatment of monkeys used ’s firm Neuralink generated a considerable amount of negative publicity a few years back.

Manufacturers of neurotechnology systems often look to a network of suppliers of components and engineering services to get their products to market faster and more economically. These supplier firms offer critical components such as batteries, housings, leads, and interconnects. Recently, several firms in this area made announcements or joined forces in an effort to attract more customers from the neurotech industry.